Show simple item record

dc.contributor.authorSingh, Babita
dc.contributor.authorPandey, Shivani
dc.contributor.authorRumman, Mohammad
dc.contributor.authorKumar, Shashank
dc.contributor.authorKushwaha, Prem Prakash
dc.contributor.authorVerma, Rajesh
dc.contributor.authorMahdi, Abbas Ali
dc.date.accessioned2024-01-16T14:23:07Z
dc.date.available2024-01-16T14:23:07Z
dc.date.issued2021-03-16T00:00:00
dc.identifier.issn16639812
dc.identifier.urihttps://doi.org/10.3389/fphar.2021.616413
dc.identifier.urihttp://kr.cup.edu.in/handle/32116/2845
dc.description.abstractEthnopharmacological Relevance: Parkinson�s disease (PD) is characterized by progressive death of dopaminergic neurons. The presently used medicines only tackle the symptoms of PD, but none makes a dent on the processes that underpin the disease�s development. Herbal medicines have attracted considerable attention in recent years. Bacopa monnieri (L.) Wettst (Brahmi) has been used in Indian Ayurvedic medicine to enhance memory and intelligence. Herein, we assessed the neuroprotective role of Bacopa monnieri (L.) Wettst on Parkinson�s disease. Aim of the Study: Bacopa monnieri (L.) Wettst, a medicinal herb, is widely used as a brain tonic. We investigated the neuroprotective and neurorescue properties of Bacopa monnieri (L.) Wettst extract (BME) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of PD. Materials and Methods: The mice model of MPTP-induced PD is used in the study. In the neuroprotective (BME + MPTP) and neurorescue (MPTP + BME) experiments, the animals were administered 40�mg/kg body weight BME orally before and after MPTP administration, respectively. Effect of BME treatment was evaluated by accessing neurobehavioral parameters and levels of dopamine, glutathione, lipid peroxide, and nitrites. An in silico study was performed using AutoDock Tools 1.5.6 (ADT). Results: A significant recovery in behavioral parameters, dopamine level, glutathione level, lipid peroxides, and nitrite level was observed in BME-treated mice. Treatment with BME before or after MPTP administration has a protective effect on dopaminergic neurons, as evidenced by a significant decrease in GFAP immunostaining and expression of inducible nitric oxide synthase (iNOS) in the substantia nigra region; however, the degree of improvement was more prominent in mice receiving BME treatment before MPTP administration. Moreover, the in silico study revealed that the constituents of BM, including bacosides, bacopasides, and bacosaponins, can inactivate the enzyme monoamine oxidase B, thus preventing the breakdown of MPTP to MPP+. Conclusion: Our results showed that BME exerts both neuroprotective and neurorescue effects against MPTP-induced degeneration of the nigrostriatal dopaminergic neurons. Moreover, BME may slow down the disease progression and delay the onset of neurodegeneration in PD. � Copyright � 2021 Singh, Pandey, Rumman, kumar, Kushwaha, Verma and Mahdi.en_US
dc.language.isoen_USen_US
dc.publisherFrontiers Media S.A.en_US
dc.subjectantioxidantsen_US
dc.subjectBacopa monnierien_US
dc.subjectiNOSen_US
dc.subjectneurodegenerationen_US
dc.subjectsubstantia nigraen_US
dc.titleNeuroprotective and Neurorescue Mode of Action of Bacopa monnieri (L.) Wettst in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson�s Disease: An In Silico and In Vivo Studyen_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fphar.2021.616413
dc.title.journalFrontiers in Pharmacologyen_US
dc.type.accesstypeOpen Accessen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record